396 related articles for article (PubMed ID: 17142622)
1. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk.
Humphries SE; Whittall RA; Hubbart CS; Maplebeck S; Cooper JA; Soutar AK; Naoumova R; Thompson GR; Seed M; Durrington PN; Miller JP; Betteridge DJ; Neil HA;
J Med Genet; 2006 Dec; 43(12):943-9. PubMed ID: 17142622
[TBL] [Abstract][Full Text] [Related]
2. The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men.
Scartezini M; Hubbart C; Whittall RA; Cooper JA; Neil AH; Humphries SE
Clin Sci (Lond); 2007 Dec; 113(11):435-41. PubMed ID: 17550346
[TBL] [Abstract][Full Text] [Related]
3. Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia.
Grenkowitz T; Kassner U; Wühle-Demuth M; Salewsky B; Rosada A; Zemojtel T; Hopfenmüller W; Isermann B; Borucki K; Heigl F; Laufs U; Wagner S; Kleber ME; Binner P; März W; Steinhagen-Thiessen E; Demuth I
Atherosclerosis; 2016 Oct; 253():88-93. PubMed ID: 27596133
[TBL] [Abstract][Full Text] [Related]
4. Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation.
Mabuchi H; Nohara A; Noguchi T; Kobayashi J; Kawashiri MA; Inoue T; Mori M; Tada H; Nakanishi C; Yagi K; Yamagishi M; Ueda K; Takegoshi T; Miyamoto S; Inazu A; Koizumi J;
Atherosclerosis; 2014 Sep; 236(1):54-61. PubMed ID: 25014035
[TBL] [Abstract][Full Text] [Related]
5. Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9.
Humphries SE; Neely RD; Whittall RA; Troutt JS; Konrad RJ; Scartezini M; Li KW; Cooper JA; Acharya J; Neil A
Clin Chem; 2009 Dec; 55(12):2153-61. PubMed ID: 19797716
[TBL] [Abstract][Full Text] [Related]
6. Novel functional APOB mutations outside LDL-binding region causing familial hypercholesterolaemia.
Alves AC; Etxebarria A; Soutar AK; Martin C; Bourbon M
Hum Mol Genet; 2014 Apr; 23(7):1817-28. PubMed ID: 24234650
[TBL] [Abstract][Full Text] [Related]
7. Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients.
Slimani A; Jelassi A; Jguirim I; Najah M; Rebhi L; Omezzine A; Maatouk F; Hamda KB; Kacem M; Rabès JP; Abifadel M; Boileau C; Rouis M; Slimane MN; Varret M
Atherosclerosis; 2012 May; 222(1):158-66. PubMed ID: 22417841
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the frequency and spectrum of mutations recognised to cause familial hypercholesterolaemia in routine clinical practice in a UK specialist hospital lipid clinic.
Futema M; Whittall RA; Kiley A; Steel LK; Cooper JA; Badmus E; Leigh SE; Karpe F; Neil HA; ; Humphries SE
Atherosclerosis; 2013 Jul; 229(1):161-8. PubMed ID: 23669246
[TBL] [Abstract][Full Text] [Related]
9. Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing.
Humphries SE; Cranston T; Allen M; Middleton-Price H; Fernandez MC; Senior V; Hawe E; Iversen A; Wray R; Crook MA; Wierzbicki AS
J Mol Med (Berl); 2006 Mar; 84(3):203-14. PubMed ID: 16389549
[TBL] [Abstract][Full Text] [Related]
10. Multiplex ARMS analysis to detect 13 common mutations in familial hypercholesterolaemia.
Taylor A; Tabrah S; Wang D; Sozen M; Duxbury N; Whittall R; Humphries SE; Norbury G
Clin Genet; 2007 Jun; 71(6):561-8. PubMed ID: 17539906
[TBL] [Abstract][Full Text] [Related]
11. Leucine 10 allelic variant in signal peptide of PCSK9 increases the LDL cholesterol-lowering effect of statins in patients with familial hypercholesterolaemia.
Pisciotta L; Sallo R; Rabacchi C; Wunsch A; Calandra S; Bertolini S
Nutr Metab Cardiovasc Dis; 2012 Oct; 22(10):831-5. PubMed ID: 21920719
[TBL] [Abstract][Full Text] [Related]
12. Lipid profile and genetic status in a familial hypercholesterolemia pediatric population: exploring the LDL/HDL ratio.
Di Taranto MD; de Falco R; Guardamagna O; Massini G; Giacobbe C; Auricchio R; Malamisura B; Proto M; Palma D; Greco L; Fortunato G
Clin Chem Lab Med; 2019 Jun; 57(7):1102-1110. PubMed ID: 30710474
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries.
Futema M; Ramaswami U; Tichy L; Bogsrud MP; Holven KB; Roeters van Lennep J; Wiegman A; Descamps OS; De Leener A; Fastre E; Vrablik M; Freiberger T; Esterbauer H; Dieplinger H; Greber-Platzer S; Medeiros AM; Bourbon M; Mollaki V; Drogari E; Humphries SE
Atherosclerosis; 2021 Feb; 319():108-117. PubMed ID: 33508743
[TBL] [Abstract][Full Text] [Related]
14. Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations.
Futema M; Plagnol V; Li K; Whittall RA; Neil HA; Seed M; ; Bertolini S; Calandra S; Descamps OS; Graham CA; Hegele RA; Karpe F; Durst R; Leitersdorf E; Lench N; Nair DR; Soran H; Van Bockxmeer FM; ; Humphries SE
J Med Genet; 2014 Aug; 51(8):537-44. PubMed ID: 24987033
[TBL] [Abstract][Full Text] [Related]
15. Genetic analysis of familial hypercholesterolaemia in Western Australia.
Hooper AJ; Nguyen LT; Burnett JR; Bates TR; Bell DA; Redgrave TG; Watts GF; van Bockxmeer FM
Atherosclerosis; 2012 Oct; 224(2):430-4. PubMed ID: 22883975
[TBL] [Abstract][Full Text] [Related]
16. Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia.
Ohta N; Hori M; Takahashi A; Ogura M; Makino H; Tamanaha T; Fujiyama H; Miyamoto Y; Harada-Shiba M
J Clin Lipidol; 2016; 10(3):547-555.e5. PubMed ID: 27206942
[TBL] [Abstract][Full Text] [Related]
17. Genetic defects causing familial hypercholesterolaemia: identification of deletions and duplications in the LDL-receptor gene and summary of all mutations found in patients attending the Hammersmith Hospital Lipid Clinic.
Tosi I; Toledo-Leiva P; Neuwirth C; Naoumova RP; Soutar AK
Atherosclerosis; 2007 Sep; 194(1):102-11. PubMed ID: 17094996
[TBL] [Abstract][Full Text] [Related]
18. Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy.
Bertolini S; Pisciotta L; Rabacchi C; Cefalù AB; Noto D; Fasano T; Signori A; Fresa R; Averna M; Calandra S
Atherosclerosis; 2013 Apr; 227(2):342-8. PubMed ID: 23375686
[TBL] [Abstract][Full Text] [Related]
19. Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia.
Pisciotta L; Priore Oliva C; Cefalù AB; Noto D; Bellocchio A; Fresa R; Cantafora A; Patel D; Averna M; Tarugi P; Calandra S; Bertolini S
Atherosclerosis; 2006 Jun; 186(2):433-40. PubMed ID: 16183066
[TBL] [Abstract][Full Text] [Related]
20. The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation.
Noguchi T; Katsuda S; Kawashiri MA; Tada H; Nohara A; Inazu A; Yamagishi M; Kobayashi J; Mabuchi H
Atherosclerosis; 2010 May; 210(1):166-72. PubMed ID: 20006333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
